Investing.com -- Today, the U.S. Food and Drug Administration (FDA) gave its approval to Vertex Pharmaceuticals' (NASDAQ: NASDAQ:VRTX) Journavx (suzetrigine) 50 milligram oral tablets. This new drug ...
The FDA has accepted for Priority Review the NDA for vatiquinone for the treatment of children and adults living with Friedreich ataxia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback